OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
Clinical trial NCT03390296 · COMPLETED
Trial details
- NCT number
- NCT03390296
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-27
- Primary completion
- 2022-02-04
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.